Servier India, the Indian arm of the French pharmaceutical group Servier, has launched a biomarker testing initiative in collaboration with genomic laboratories MedGenome and Strand Life Sciences to improve access to molecular diagnostics for patients with acute myeloid leukaemia (AML) and cholangiocarcinoma (CCA) across India.

Under this initiative, a customised panel of biomarker tests will be made available at subsidised rates to healthcare professionals across both private and government sectors. As part of the programme, testing for IDH1 and IDH2 mutations, which are key genetic markers that guide treatment decisions, will be provided free of cost to the government sector. Advertisement

Acute myeloid leukaemia (AML) is an aggressive cancer of the blood and bone marrow that disrupts

See Full Page